A Randomized Trial Comparing Plasma Drug Concentrations and Efficacies between 2 Nonnucleoside Reverse‐Transcriptase Inhibitor–Based Regimens in HIV‐Infected Patients Receiving Rifampicin: The N2R Study-Reference-Cited by-同舟云学术

A Randomized Trial Comparing Plasma Drug Concentrations and Efficacies between 2 Nonnucleoside Reverse‐Transcriptase Inhibitor–Based Regimens in HIV‐Infected Patients Receiving Rifampicin: The N2R Study

Published:2009-06-15 Issue:12 Volume:48 Page:1752-1759
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:CLIN INFECT DIS

Author:

Manosuthi Weerawat,Sungkanuparph Somnuek,Tantanathip Preecha,Lueangniyomkul Aroon,Mankatitham Wiroj,Prasithsirskul Wisit,Burapatarawong Sunantha,Thongyen Supeda,Likanonsakul Sirirat,Thawornwa Unchana,Prommool Vilaiwan,Ruxrungtham Kiat,

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/48/12/1752/915924/48-12-1752.pdf

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Landscape of TB Infection and Prevention among People Living with HIV;Pathogens;2022-12-16

2. Brief Report: Efficacy and Safety of Efavirenz, Raltegravir, and Dolutegravir in HIV-1/TB Coinfection. A Multicenter Retrospective Cohort Study in France;JAIDS Journal of Acquired Immune Deficiency Syndromes;2022-09-01

3. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial;The Lancet Infectious Diseases;2021-06

4. Evaluating the impact of antiretroviral and antiseizure medication interactions on treatment effectiveness among outpatient clinic attendees with HIV in Zambia;Epilepsia;2020-10-21

5. Switching protease inhibitors to rilpivirine in HIV‐positive individuals with complete viral suppression and without prior HIV drug resistance in a resource‐limited setting: a randomized controlled trial;Journal of the International AIDS Society;2020-04